XML 50 R38.htm IDEA: XBRL DOCUMENT v3.4.0.3
Segment Information and Concentration of Business Risk (Details)
$ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2016
USD ($)
Segment
Partner
Mar. 31, 2015
USD ($)
Dec. 31, 2015
USD ($)
Partner
Segment Information and Concentration of Business Risk [Abstract]      
Number of reportable segments | Segment 2    
Revenue [Abstract]      
Research and development $ 35,214 $ 61,892  
Licensing and royalty 1,660 691  
Total revenue 36,874 62,583  
Loss from operations (54,652) (9,330)  
Total assets 875,819   $ 947,900
Operating Segments [Member] | Ionis Core [Member]      
Revenue [Abstract]      
Research and development 35,214 61,892  
Licensing and royalty 1,660 691  
Total revenue 36,874 62,583  
Loss from operations (38,567) (2,325)  
Total assets 936,903   995,852
Operating Segments [Member] | Akcea Therapeutics [Member]      
Revenue [Abstract]      
Research and development 0 0  
Licensing and royalty 0 0  
Total revenue 0 0  
Loss from operations (16,049) $ (7,005)  
Total assets 65,131   66,306
Elimination of Intercompany Activity [Member]      
Revenue [Abstract]      
Research and development 0    
Licensing and royalty 0    
Total revenue 0    
Loss from operations (36)    
Total assets $ (126,215)   $ (114,258)
Revenue [Member] | Partner A [Member]      
Significant Partners [Abstract]      
Concentration percentage 58.00% 63.00%  
Revenue [Member] | Partner B [Member]      
Significant Partners [Abstract]      
Concentration percentage 14.00% 26.00%  
Contracts Receivables [Member] | Significant Partners [Member]      
Significant Partners [Abstract]      
Concentration percentage 98.00%   99.00%
Number of significant partners | Partner 2   2